```
=> d his

     (FILE 'HOME' ENTERED AT 12:27:27 ON 11 JUL 2002)

     FILE 'REGISTRY' ENTERED AT 12:27:32 ON 11 JUL 2002
L1             STRUCTURE UPLOADED
L2          1897 S L1 FULL
L3             STRUCTURE UPLOADED
L4             8 S L3 FULL SUB=L2

     FILE 'USPATFULL' ENTERED AT 12:30:57 ON 11 JUL 2002
L5             3 S L4

     FILE 'CAPLUS' ENTERED AT 12:34:19 ON 11 JUL 2002
L6             3 S L4/THU

     FILE 'MARPAT' ENTERED AT 12:36:51 ON 11 JUL 2002
L7          1256 S L4 FULL
L8          1253 S L7/COM
L9             0 S L8(L)TREATMENT
L10            0 S L8(L)TREAT?
```

=> d ibib ab hitstr 1-3

L5 ANSWER 1 OF 3 USPATFULL
ACCESSION NUMBER: 96:29480 USPATFULL
TITLE: Non-specific reaction suppressor
INVENTOR(S): Ito, Michio, Indianapolis, IN, United States
Sugawa, Satoshi, Machida, Japan
Yanagida, Atsushi, Carmel, IN, United States
PATENT ASSIGNEE(S): Mitsubishi Kasei Corporation, Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5506151		19960409
APPLICATION INFO.:	US 1994-194475		19940209 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ceperley, Mary E.
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 575
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A non-specific reaction suppressor for immunoassays having the formula: ##STR1## where R.sub.1, R.sub.2, Y, X, and R.sub.3 are defined in the specification.
IT **32897-26-0**, 1-Ethyl3-(3-dimethylaminopropyl)urea
(immunoassay uses latex particle-immobilized immunoreactant and nonspecific reaction suppressor)
RN 32897-26-0 USPATFULL
CN Urea, N-[3-(dimethylamino)propyl]-N'-ethyl- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 3 USPATFULL
ACCESSION NUMBER: 93:35827 USPATFULL
TITLE: Process for production of water-soluble carbodiimide
INVENTOR(S): Yoneyama, Takahiro, Matsudo, Japan
Odagiri, Masaki, Ushiku, Japan
Imanari, Makoto, Ami, Japan
PATENT ASSIGNEE(S): Research Association for Utilization of Light Oil, Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5208378		19930504
APPLICATION INFO.:	US 1991-732123		19910718 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1990-189414	19900719

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hollrah, Glennon H.
ASSISTANT EXAMINER: O'Sullivan, Peter G.
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 239
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for the production of a water-soluble carbodiimide, which comprises

(1) allowing ethyl isothiocyanate to react with N,N-dimethyl-1,3-propanediamine in an aromatic hydrocarbon solvent (first reaction step),

(2) removing hydrogen sulfide from a thiourea derivative formed in the first reaction step upon adding a hydrogen sulfide removing agent without isolating the thiourea derivative (second reaction step), and

(3) recovering a water-soluble carbodiimide from the resulting reaction mixture.
IT **32897-26-0P**
(prepn. and dehydrosulfurization of)
RN 32897-26-0 USPATFULL
CN Urea, N-[3-(dimethylamino)propyl]-N'-ethyl- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 3 USPATFULL
ACCESSION NUMBER: 85:75074 USPATFULL
TITLE: Carboxyl anchored immobilized antibodies
INVENTOR(S): Arnold, Edward C., Naperville, IL, United States
PATENT ASSIGNEE(S): UOP Inc., Des Plaines, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4560504		19851224
APPLICATION INFO.:	US 1984-678953		19841206 (6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schain, Howard E.
LEGAL REPRESENTATIVE: McBride, Thomas K., Page II, William H., Snyder, Eugene I.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 368
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An immobilized antibody system can be made by reacting an aminated core support with an antibody in the presence of a condensing agent which promotes the formation of the amide linkage. The immobilized antibody system is highly resistant to leaching, may be made incompressible, sterilizable, and pyrogen-free. Such an immobilized antibody system is well suited for repeated use with minimal change in its physical and biochemical properties.
IT **4607-26-5**
(condensing agent, in carboxyl group contg. antibodies immobilization on aminated support)
RN 4607-26-5 USPATFULL
CN Urea, N-[3-(dimethylamino)propyl]-N'-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



=> d ibib ab hitstr 1-3

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:416773 CAPLUS
DOCUMENT NUMBER: 135:46190
TITLE: Synthesis and use of substituted pyrrolo[2,3-b]pyrimidines as selective adenosine A1, A2a and A3 receptor antagonists
INVENTOR(S): Castelhano, Arlindo L.; McKibben, Bryan; Witter, David J.
PATENT ASSIGNEE(S): Osi Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 368 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001039777	A1	20010607	WO 2000-US32702	20001201

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-454074 A 19991202
US 1999-454075 A 19991202
US 1999-454254 A 19991202
OTHER SOURCE(S): MARPAT 135:46190
AB The synthesis of compds. I, their binding to adenosine receptors and use are described [wherein; R1, R2 = H, (un)substituted alkyl or NR1R2 = (un)substituted 4-8 membered ring; R3 = (un)substituted 4-6 membered (arom.) ring; R4, R5 = H, (un)substituted alkyl, aryl (with some exceptions)]. Over 100 examples are provided. Intermediate 4-chloro-7H-pyrrolo[2,3-d]pyrimidines were prepd. by several routes from appropriately substituted cyano-pyrroles. Thus, 4-chloro-2-(4-pyridyl)-7H-pyrrolo[2,3-d]pyrimidine hydrochloride was reacted with D-prolinol (2.3 mol equiv) in DMSO at 120.degree.C for 18 h to yield III in 13% yield after purifn. Compd. I [R1 = AcNHCH2CH2; R2 = H; R3 = Ph; R4, R5 = Me; II] exhibited selective binding to adenosine receptor A1 with IC50 = 82.8 nM. Compd. II also had Ki = 9.8 nM (vs. Ki = 7.1 for control ligand 8-cyclopentyl-1,3-dipropylxanthine (DPCPX)). Pyrimidine III binds 5 times more selectively to adenosine receptor A2a than A1, A2b or A3 (no data). Compd. I [R1 = AcNH(CH2)4; R2 = H; R3 = Ph; R4, R5 = Me] is 10 times more selective for A3 than the other receptor subtypes. ClogP (calcd. partition coeff. between octanol and H2O) values were detd. for selected example compds. Claimed uses of I includes administration of a systemic formulation (i.e. ophthalmic) for the treatment of a disease assocd. with A1, A2a, and A3 adenosine receptors in a subject.
IT **343632-35-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and use of substituted 7H-pyrrolo[2,3-b]pyrimidines as

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2002 ACS (Continued)
selective adenosine A1, A2a and A3 receptor antagonists)
RN 343632-35-9 CAPLUS
CN Urea, N-[3-[(5,6-dimethyl-2-phenyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]propyl]-N'-ethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:338479 CAPLUS
DOCUMENT NUMBER: 134:353175
TITLE: Preparation of amides and ureas as activators of soluble guanylate cyclase
INVENTOR(S): Selwood, David; Glen, Robert; Reynolds, Karen; Wishart, Grant
PATENT ASSIGNEE(S): University College London, UK
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032604	A1	20010510	WO 2000-GB4249	20001106

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 1999-26286 A 19991105
US 2000-201382P P 20000502
OTHER SOURCE(S): MARPAT 134:353175
AB The title compds. R4PZNR1R2 [I; R1, R2 = alkyl; R1R2 together form alkylene; Z = alkylene; P = a direct bond, X, Y, W, XY, YW, XYW (wherein W = O, S, NR3; R3 = H, alkyl; Y = UV; V = a direct bond, alkylene; U = CS, CO, SO2, C(:NR); R = H, OH, alkyl; X = O, NR6; R6 = H, alkyl, alkenyl, etc.); R4 = alkyl, alkenyl, alkynyl, etc.], useful in the activation of sol. guanylate cyclase, were prepd. E.g., synthesis of the urea II, starting with 4-bromoaniline and 1-(3-aminopropyl)pyrrolidine, was given. Biol. data for compds. I (e.g., IC50 for inhibition of platelet aggregation) were presented.
IT **32897-26-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amides and ureas as activators of sol. guanylate cyclase)
RN 32897-26-0 CAPLUS
CN Urea, N-[3-(dimethylamino)propyl]-N'-ethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:725451 CAPLUS
DOCUMENT NUMBER: 133:286497
TITLE: Immunomodulatory compositions and methods of use thereof
INVENTOR(S): Onderdonk, Andrew B.; Tzianabos, Arthur O.; Miller, Robert J.; Calias, Pericles
PATENT ASSIGNEE(S): Genzyme Corporations, USA
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059490	A2	20001012	WO 2000-US9087	20000406
WO 2000059490	A3	20010215		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1171136	A2	20020116	EP 2000-920167	20000406

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: US 1999-128177P P 19990406
US 2000-188422P P 20000310
WO 2000-US9087 W 20000406
OTHER SOURCE(S): MARPAT 133:286497
AB The invention relates to immunomodulatory compns. and related methods. The immunomodulatory compns. are useful for the prevention of sepsis and the treatment and prevention of diseases assocd. with inflammation and/or NOS. CM-cellulose/N-ethyl-N'-(3-dimethylaminopropyl)urea formulations are described.
IT **32897-26-0 121007-41-8**
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(immunomodulatory compns.)
RN 32897-26-0 CAPLUS
CN Urea, N-[3-(dimethylamino)propyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 121007-41-8 CAPLUS
CN 1-Propanaminium, 3-[[(ethylamino)carbonyl]amino]-N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2002 ACS (Continued)